Chronic Idiopathic Urticaria Clinical Trial
Official title:
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02814630 -
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
|
N/A | |
| Completed |
NCT01803763 -
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00536380 -
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
|
Phase 4 | |
| Completed |
NCT03183024 -
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody
|
Phase 4 | |
| Completed |
NCT00757562 -
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)
|
Phase 3 | |
| Completed |
NCT03858634 -
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
|
Phase 2 | |
| Completed |
NCT01292473 -
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
|
Phase 3 | |
| Completed |
NCT00866788 -
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
|
Phase 2 | |
| Recruiting |
NCT01635127 -
Efficacy Study of Canakinumab to Treat Urticaria
|
Phase 2 | |
| Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
| Recruiting |
NCT02031679 -
Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
|
Phase 2 | |
| Recruiting |
NCT00346606 -
The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria
|
Phase 4 | |
| Completed |
NCT01287117 -
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
|
Phase 3 | |
| Completed |
NCT01264939 -
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
|
Phase 3 | |
| Completed |
NCT03406325 -
Mast Cell Activation Test in Allergic Disease
|
||
| Not yet recruiting |
NCT04175704 -
Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria
|
Phase 1 | |
| Withdrawn |
NCT01030120 -
Etanercept for the Treatment of Chronic Urticaria
|
Phase 2/Phase 3 | |
| Completed |
NCT00264303 -
CUTE (Chronic Urticaria Treatment Evaluation)
|
Phase 4 | |
| Recruiting |
NCT05774639 -
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
|
Phase 3 | |
| Completed |
NCT01599637 -
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
|
Phase 2 |